AMA Submits Agentic AI Healthcare Regulation Recommendations to FDA: Three-Pillar Framework Reshapes US Healthcare AI Governance
On October 19, 2026, the American Medical Association (AMA) formally submitted detailed recommendations to the US Food and Drug Administration (FDA) regarding the regulation of generative AI (GenAI) medical devices. The recommendations respond to the FDA's August 18, 2026 discussion paper, calling for a risk-based regulatory framework and explicitly establishing the "physician-led" principle. Industry analysts simultaneously characterize the overall federal regulatory posture as a "three-pillar" framework, expected to fully reshape healthcare AI governance by 2028.
Background: FDA Discussion Paper Triggers Broad Industry Response
On August 18, 2026, the FDA published a discussion paper on generative AI medical devices, seeking public input to develop a regulatory approach for this rapidly evolving field. The AMA's response represents the most comprehensive position from a medical professional organization to date.
The AMA's recommendations emphasize several core positions:
- Risk-Based Regulation: Different risk levels of AI should be subject to different regulatory requirements
- Centrality of Physician Expertise: Physician expertise should inform standards rather than serve as an after-the-fact safety net
- Robust Post-Market Monitoring: Systematic post-market performance monitoring mechanisms are needed
- Meaningful Clinical Evidence: AI system approvals should be based on effectiveness evidence from real clinical environments
The Three-Pillar Regulatory Framework Explained
Industry analysts characterize the overall US federal AI healthcare regulatory posture as three complementary pillars:
Pillar 1: FDA (Medical Devices)
The FDA continues as the primary regulator for AI medical devices, overseeing tools that produce diagnostic or therapeutic outputs.
Key Development: SKOUT Autonomous de novo Authorization
The FDA's recent de novo authorization of "SKOUT Autonomous" established a template for future autonomous AI clearances, containing four core elements:
| Element | Description |
|---|---|
| Narrow Indications | Defining precise clinical settings and input conditions where AI can operate without real-time human concurrence |
| Defined Thresholds | Mechanically enforceable boundaries for AI operation (e.g., specific polyp sizes) that trigger return to clinician oversight |
| Mandatory Registries | Requirement for ongoing, independent, per-case data collection by centers using autonomous mode |
| Named Stopping Rules | Pre-market agreements defining specific performance drift metrics that trigger immediate withdrawal of autonomous authorization |
Pillar 2: HHS (Autonomous Agents)
The Department of Health and Human Services (HHS) is developing new regulatory frameworks for autonomous agents (e.g., triage bots, outreach systems). These systems fall outside traditional device definitions because they don't technically perform a diagnosis, but their autonomous decision-making capabilities still require oversight.
HHS regulatory focus areas include:
- Resolving conflicts between federal regulations and state-level scope-of-practice laws
- Documentation accountability in electronic health records (EHR)
- Liability allocation between vendors and clinicians
Pillar 3: ONC (Data Layer)
The Office of the National Coordinator for Health Information Technology (ONC) leverages the HTI-2 enforcement framework to create an official registry of clinical decision support (CDS) algorithms, including autonomous agents.
This registry will become a public artifact auditable by regulators, researchers, and attorneys, dramatically improving AI system transparency and accountability.
State-Level Legislation: Human Oversight Requirements Rapidly Spreading
While the federal framework gradually takes shape, states have already enacted legislation, forming three main trends:
Human-in-the-Loop Requirements
Multiple states (including Alabama, Iowa, Maryland, Nebraska) have enacted laws requiring that a licensed human must be involved in care or coverage denials, preventing AI from being the "sole basis" for such decisions.
Disclosure Mandates
Increasing numbers of states require organizations to disclose AI use in clinical documentation or patient communications.
Mental Health Restrictions
A cluster of states (including Vermont, Maine, Rhode Island, Illinois) have enacted strict limitations or explicit prohibitions on AI providing direct mental health services.
Industry Status: AI Becomes "Table Stakes," But Public Trust Declines
According to April 2026 surveys, American public trust in healthcare AI has fallen to 42%, down from 52% in 2024. This decline reflects growing public awareness of AI "hallucination" risks and a more nuanced assessment of AI's role in diagnostics and decision-making.
Despite this, AI penetration in healthcare continues to rise:
- Ambient AI scribes have been proven to save clinicians significant time per encounter
- Autonomous AI platforms in revenue cycle management (RCM) are rapidly expanding
- AKASA's autonomous AI platform achieves up to 93% touchless medical coding
Asia-Pacific Perspective: Localization Challenges for Regulatory Frameworks
The US three-pillar framework provides important reference for Asia-Pacific, but different regions face distinct localization challenges:
Australia: The Therapeutic Goods Administration (TGA) is updating AI medical device guidelines, with the final version expected in early 2027.
Singapore: The Health Sciences Authority (HSA) has established a fast-track approval pathway for AI medical devices, but regulation of autonomous agents is still under study.
Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) is developing post-market monitoring requirements for AI medical devices, aligned with FDA's mandatory registry direction.
China: The National Medical Products Administration (NMPA) has published AI medical device review guidelines, but specific regulatory frameworks for generative AI are still being developed.
Outlook: Regulatory Milestones Before 2028
According to industry analyst predictions, key milestones in US healthcare AI regulation include:
- End of 2026: HHS completes public consultation on autonomous agent regulatory framework
- H1 2027: ONC officially launches CDS algorithm registry
- End of 2027: FDA publishes final regulatory guidance for generative AI medical devices
- 2028: Three-pillar framework fully implemented, forming a complete healthcare AI regulatory ecosystem
For healthcare AI companies operating in Asia-Pacific, closely monitoring the evolution of the US regulatory framework is critical, as US regulatory standards often become the de facto global standard for healthcare AI markets.
